Why is Tyra Biosciences stock plunging today?
Tyra Biosciences (TYRA) stock fell 31.1% to $18.42 after Phase 2 trial results for dabogratinib showed a 64% complete response rate, below the 70% analyst consensus. Piper Sandler and H.C. Wainwright had modeled a 70% rate as the success threshold. The stock had risen 13% the prior week. Broader market caution added to the decline.
How this was made
The 30-second read
Why it matters
The 64% complete response rate fell short of the 70% threshold set by analysts, triggering a sharp sell‑off.
Market read
The miss could dampen investor enthusiasm for FGFR3‑targeted therapies and affect related biotech equities.
What to watch
Management plans a 70 mg cohort, which may improve efficacy signals in future reads.
Background
Tyra Biosciences announced Phase 2 results for oral dabogratinib in FGFR3‑altered NMIBC, a key step toward a registrational strategy.
Ticker impact
Tyra Biosciences stock fell 31.1% in pre‑market trading after Phase 2 SURF302 data missed the 70% complete response benchmark.
Further downside pressure expected if no corrective data emerge.
Large pre‑market move and clear efficacy shortfall indicate heightened sell‑off risk.
Market effects
Biotech sector may see broader risk aversion as investors reassess FGFR3‑targeted programs.
US biotech stocks could face heightened volatility in early trading.
Limited to investors with exposure to US‑listed biotech firms.
Counterpoint
If the safety profile remains strong, the data could still support a later‑stage trial and a rebound.
Key entities
- companyTyra Biosciences
US‑listed biotech developing FGFR3 inhibitors.
- analystPiper Sandler
Overweight rating holder that set the 70% benchmark.
